Olanzapine (Zyprexa):charactirestics of a new antipsychotic

Bibliography

• TAMMINGA CA: The neuropsychiatry of schizophrenia. In: Textbook of Neuropsychiatiy. Yodofsky SC, Hales RE (Eds.), APA Press, Inc., Washington, DC (1997) 855–882.
   Google Scholar
• CARPENTER WT JR, BUCHANAN RW: Schizophrenia. New Engl. J. Med. (1994) 330:681–690.
   PubMed Web of Science ®Google Scholar
• DELNAY J, DENIKER P: Le traitement des psychoses par une méthode neurolytique dérivée de l'hibernothera-pie. In: Congres des Médecins Aliénistes et Neurologistes de France. Luxembourg (1952) 497–502.
   Google Scholar
• CARLSSON A, LINDQUIST M: Effect of chlorpromazine and haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol. Toxicol. (1963) 20:140–144.
   PubMedGoogle Scholar
• CREESE I, BURT DR, SNYDER SH: Dopamine receptor binding predicts clinical and pharmacological poten-cies of antischizophrenic drugs. Science (1976) 192:481–483.
   PubMed Web of Science ®Google Scholar
• SEEMAN P: Dopamine receptors and psychosis. ScL Med.(1995) 2:28–37.
   Google Scholar
• KLEIN DF, DAVIS JM: Diagnosis and Drug Treatment of Psy-chiatric Disorders. The Williams and Wilkins Company, Bal-timore, Maryland (1969).
   Google Scholar
• TAMMINGA CA, SHIRAKAWA O, CONLEY RR: Nontargetactions of neuroleptics. Neuroleptic side effects and tardive dyskinesia. In: New Generation of Antipsychotic Drugs: Novel Mechanisms of Action. Brunello N, Mendlewicz J, Racagni G (Eds.), Intern. Acad. Biomed. Drug Res., Basel, Karger (1993) 67–76.
   Google Scholar
• KANE J, HONIGFELD G, SINGER J, MELTZER H: Clozapinefor the treatment-resistant schizophrenic: a double-blind comparison versus chlorpromazine/benztro-pine. Arch. Gen. PsychiaL (1988) 45:789–796.
   PubMed Web of Science ®Google Scholar
• STOCKTON ME, RASMUSSEN K: Electrophysiological ef-fects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurones. Neuropsychopharma-cology (1996) 14:97–104.
   PubMed Web of Science ®Google Scholar
• ROBERTSON GS, FIBIGER HC: Effects of olanzapine onregional c-fos expression in rat forebrain. Neuropsycho-pharmacology (1996) 14:105–110.
   PubMed Web of Science ®Google Scholar
• HOFFMAN DC, DONOVAN H: Catalepsy as a rodent model for detecting antipsychotic drugs with extrapy-ramidal side effect liability. Psychopharmacology (1995) 120:128–133.
   PubMed Web of Science ®Google Scholar
• CASEY DE: Behavioral effects of sertindole, risperidone,clozapine and haloperidol in Cebus monkeys. Psycho-pharmacology (1996) 124:134–140.
   PubMed Web of Science ®Google Scholar
• GAO X-M, SAKAI K, TAMMINGA CA: Chronic olanzapineor sertindole treatment results in reduced oral dyskine-sias in rats compared to haloperidol. NeuroscL Lett. (Sub-mitted).
   Google Scholar
• CORBETT R, CAMACHO F, WOODS AT et al.: Antipsy-chotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviours. Psychophar-macology (1995) 120:67–74.
   PubMed Web of Science ®Google Scholar
• BAKSHI VP, GEYER MA: Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology (1995) 122:198–201.
   PubMed Web of Science ®Google Scholar
• MOORE NA, CALLIGARO DO, WONG DT, BYMASTER F, TYE NC: The pharmacology of olanzapine and other new antipsychotic agents. Curr. Opin. Invest. Drugs (1993) 2(4):281–293.
   Google Scholar
• BYMASTER FP, CALLIGARO DO, FALCONE JF et al.: Ra-dioreceptor binding profile of the atypical antipsy-chotic olanzapine. Neuropsychopharmacology (1996) 14:87–96.
   PubMed Web of Science ®Google Scholar
• SCHOTTE A, JANSSEN PFM, GOMMEREN W: Risperidonecompared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacol-ogy (1996) 124:57–73.
   PubMed Web of Science ®Google Scholar
• SEEMAN P: Therapeutic receptor-blocking concentra-tions of neuroleptics. Int. Clin. Psychopharmacol. (1995) 10 (3):5–13.
   PubMedGoogle Scholar
• ROTH BL, TANDRA S, BURGESS LH, SIBLEY DR, MELTZER HY: D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology (1995) 120:365–368.
   PubMed Web of Science ®Google Scholar
• ROTH BL, CRAIGO SC, CHOUDHARY MS et al.: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 re-ceptors. J. Pharmacol. Exp. Ther. (1994) 268:1403–1410.
   PubMed Web of Science ®Google Scholar
• BYMASTER FP, HEMRICK-LUECKE SK, PERRY KW, FULLER RW: Neurochemical evidence for antagonism by olan-zapine of dopamine, serotonin, cci-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacol-ogy (1996) 124:87–94.
   PubMed Web of Science ®Google Scholar
• MOORE NA, REES G, SANGER G, TYE NC: Effects of olan-zapine and other antipsychotic agents on responding maintained by a conflict schedule. Behav. Pharmacol (1994) 5:196–202.
   PubMed Web of Science ®Google Scholar
• FARDE L, MACK RJ, NYBERG S, HALLDIN C: Dy occupancy, extrapyramidal side effects and antipsychotic drug treatment: a pilot study with sertindole in healthy sub-jects. Int. Clin. Psychopharmacol. (1997) 12:S3–S7.
   PubMed Web of Science ®Google Scholar
• CATLOW JT, BARTON RD, CLEMENS M et al.: Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with elec-trochemical detection. J. Chromatogr. B (1995) 668:85–90.
   PubMed Web of Science ®Google Scholar
• RING BJ, BINKLEY SN, VANDENBRANDEN M, WRIGHTON SA: In vitro interaction of the antipsychotic agent olan-zapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br. J. Clin. Pharmacol (1996) 41:181–186.
   PubMed Web of Science ®Google Scholar
• BEASLEY CM: Efficacy of olanzapine: an overview of piv-otal clinical trials. J. Clin. PsychiaL Monograph (1997) 15:16–18.
   Google Scholar
• BALDWIN DS, MONTGOMERY SA: First clinical experi-ence with olanzapine (LY 170053): results of an open-label safety and dose-ranging study in patients with schizophrenia. Int. Clin. Psychopharmacol. (1995) 10:239–244.
   PubMed Web of Science ®Google Scholar
• BEASLEY CM, SANGER T, SATTERLEE W et al.: Olanzapine versus placebo: results of a double-blind, fixed-dose ol-anzapine trial. Psychopharmacology (1996) 124:159–167.
   PubMed Web of Science ®Google Scholar
• TOLLEFSON GD, BEASLEY CM, TRAN PV et al.: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J. Psy-chiaL (1997) 154:457–465.
   PubMed Web of Science ®Google Scholar
• TOLLEFSON GD, SANGER TM: Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am. J. Psychial (1997) 154:466–474.
   PubMed Web of Science ®Google Scholar
• KANE JM: Tardive dyskinesia: epidemiological and clinical presentation. In: Psychopharmacology: The Fourth Generation of Progress. Bloom FE, Kupfer DJ (Eds.), Raven Press, New York (1995) 1485–1495.
   Google Scholar
• KECK PE, MCELROY SL: Olanzapine: a novel antipsy-chotic medication. J. New Dev. Clin. Med. (1996) 14:63–78.
   Google Scholar
• TOLLEFSON GD, TRAN PV, HAMILTON S, KUNTZ A: Olan-zapine versus risperidone in the treatment of psycho-sis. Preliminary report. Schizophrenia Res. (1997) 24:191–192.
   Web of Science ®Google Scholar
• CONLEY RR, TAMMINGA CA, BEASLEY C: Olanzapine versus chlorpromazine in therapy-refractory schizophre-nia. Schizophrenia Res. (1997) 24:190.
   Web of Science ®Google Scholar